Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1962 1
1964 1
1973 1
1974 1
1975 2
1977 1
1978 8
1979 1
1980 4
1981 3
1982 1
1983 5
1984 3
1985 7
1986 12
1987 8
1988 9
1989 11
1990 7
1991 5
1992 12
1993 22
1994 23
1995 17
1996 16
1997 31
1998 21
1999 23
2000 29
2001 33
2002 28
2003 47
2004 40
2005 36
2006 43
2007 37
2008 42
2009 46
2010 45
2011 41
2012 41
2013 48
2014 48
2015 51
2016 38
2017 46
2018 50
2019 38
2020 41
2021 40
2022 41
2023 43
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

1,160 results

Results by year

Filters applied: . Clear all
Page 1
Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes.
Wu F, Yin YY, Fan WH, Zhai Y, Yu MC, Wang D, Pan CQ, Zhao Z, Li GZ, Zhang W. Wu F, et al. EBioMedicine. 2023 Jan;87:104410. doi: 10.1016/j.ebiom.2022.104410. Epub 2022 Dec 14. EBioMedicine. 2023. PMID: 36525723 Free PMC article.
BACKGROUND: Human oligodendroglioma presents as a heterogeneous disease, primarily characterized by the isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion. ...Higher T cell/APC co-inhibition and inhibitory checkpoint levels were observed in Oligo2 tumors …
BACKGROUND: Human oligodendroglioma presents as a heterogeneous disease, primarily characterized by the isocitrate dehydrogenase (IDH …
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M, Blakeley J. Mohile NA, et al. J Clin Oncol. 2022 Feb 1;40(4):403-426. doi: 10.1200/JCO.21.02036. Epub 2021 Dec 13. J Clin Oncol. 2022. PMID: 34898238
RESULTS: Fifty-nine randomized trials focusing on therapeutic management were identified. RECOMMENDATIONS: Adults with newly diagnosed oligodendroglioma, isocitrate dehydrogenase (IDH)-mutant, 1p19q codeleted CNS WHO grade 2 and 3 should be offered radiation therapy (RT) a …
RESULTS: Fifty-nine randomized trials focusing on therapeutic management were identified. RECOMMENDATIONS: Adults with newly diagnosed ol …
Imaging of oligodendroglioma.
Smits M. Smits M. Br J Radiol. 2016;89(1060):20150857. doi: 10.1259/bjr.20150857. Epub 2016 Feb 5. Br J Radiol. 2016. PMID: 26849038 Free PMC article. Review.
Oligodendroglioma are glial tumours, predominantly occurring in adults. ...This complicates differentiation from high-grade, anaplastic oligodendroglioma, in which enhancement and increased perfusion are also common. ...
Oligodendroglioma are glial tumours, predominantly occurring in adults. ...This complicates differentiation from high-grade, anaplast …
Diffuse Infiltrating Oligodendroglioma and Astrocytoma.
van den Bent MJ, Smits M, Kros JM, Chang SM. van den Bent MJ, et al. J Clin Oncol. 2017 Jul 20;35(21):2394-2401. doi: 10.1200/JCO.2017.72.6737. Epub 2017 Jun 22. J Clin Oncol. 2017. PMID: 28640702 Review.
The new 2016 WHO brain tumor classification defines different diffuse gliomas primarily according to the presence or absence of IDH mutations ( IDH-mt) and combined 1p/19q loss. Today, the diagnosis of anaplastic oligodendroglioma requires the presence of both IDH-mt and 1 …
The new 2016 WHO brain tumor classification defines different diffuse gliomas primarily according to the presence or absence of IDH mutation …
Low-grade and anaplastic oligodendroglioma.
Van Den Bent MJ, Bromberg JE, Buckner J. Van Den Bent MJ, et al. Handb Clin Neurol. 2016;134:361-80. doi: 10.1016/B978-0-12-802997-8.00022-0. Handb Clin Neurol. 2016. PMID: 26948366 Review.
It is also equally clear that benefit to PCV chemotherapy is not limited to the 1p/19q co-deleted cases; potential other predictive factors are IDH mutations and MGMT promoter methylation. ...
It is also equally clear that benefit to PCV chemotherapy is not limited to the 1p/19q co-deleted cases; potential other predictive f …
Anaplastic oligodendroglioma and oligoastrocytoma.
van den Bent MJ. van den Bent MJ. Neurol Clin. 2007 Nov;25(4):1089-109, ix-x. doi: 10.1016/j.ncl.2007.07.013. Neurol Clin. 2007. PMID: 17964027 Review.
Until approximately 15 years ago, the diagnosis of an oligodendroglioma (OD) was merely as a pathologic entity. The only clinical relevant meaning of this histologic diagnosis was the observation that the prognosis of OD was in general better than that of astrocytic …
Until approximately 15 years ago, the diagnosis of an oligodendroglioma (OD) was merely as a pathologic entity. The only clinical rel …
Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis.
Engelhard HH, Stelea A, Mundt A. Engelhard HH, et al. Surg Neurol. 2003 Nov;60(5):443-56. doi: 10.1016/s0090-3019(03)00167-8. Surg Neurol. 2003. PMID: 14572971 Review.
In this article, the topic of oligodendroglioma and anaplastic oligodendroglioma is reviewed, highlighting the new clinical developments. ...RESULTS: The incidence of oligodendroglioma is increasing, most likely due to its improved recognition. ...
In this article, the topic of oligodendroglioma and anaplastic oligodendroglioma is reviewed, highlighting the new clinical de …
Pathology and Genetics of Gliomas.
Komori T, Muragaki Y, Chernov MF. Komori T, et al. Prog Neurol Surg. 2018;31:1-37. doi: 10.1159/000466835. Epub 2018 Jan 25. Prog Neurol Surg. 2018. PMID: 29393190 Review.
Nevertheless, the impact of tumor pathology on clinically related parameters may be frequently much better predicted by genetics, than by histological appearance of the lesion. ...Identification of those and several other genetic abnormalities in the tumor is clinically im …
Nevertheless, the impact of tumor pathology on clinically related parameters may be frequently much better predicted by genetics, tha …
A double-edged sword: The world according to Capicua in cancer.
Tanaka M, Yoshimoto T, Nakamura T. Tanaka M, et al. Cancer Sci. 2017 Dec;108(12):2319-2325. doi: 10.1111/cas.13413. Epub 2017 Oct 25. Cancer Sci. 2017. PMID: 28985030 Free PMC article. Review.
The receptor tyrosine kinase/RAS/MAPK signals downregulate CIC and relieves CIC's target genes from the transrepressional activity; CIC thus acts as an important downstream molecule of the pathway and as a tumor suppressor. CIC loss-of-function mutations are frequently observe …
The receptor tyrosine kinase/RAS/MAPK signals downregulate CIC and relieves CIC's target genes from the transrepressional activity; CIC thus …
Oligodendroglioma: pathology, molecular mechanisms and markers.
Wesseling P, van den Bent M, Perry A. Wesseling P, et al. Acta Neuropathol. 2015 Jun;129(6):809-27. doi: 10.1007/s00401-015-1424-1. Epub 2015 May 6. Acta Neuropathol. 2015. PMID: 25943885 Free PMC article. Review.
Subsequently, this codeletion appeared to not only carry diagnostic, but also prognostic and predictive information, the latter aspect only recently resolved after carefully constructed clinical trials with very long follow-up times. More recently described biomarkers, inc …
Subsequently, this codeletion appeared to not only carry diagnostic, but also prognostic and predictive information, the latter aspec …
1,160 results